The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al. axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed @RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x